Savant Capital’s Xeris Biopharma Holdings XERS Stock Holding History

Savant Capital’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-22,116	Closed	-$75K	–	1451
2024 Q4	$75K	Buy	22,116 +1	+0%	+$3	﹤0.01%	1393
2024 Q3	$63K	Buy	+22,115	New	+$56.8K	﹤0.01%	1365

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Savant Capital's XERS Position: Q1 2025 in Review

Savant Capital sold out of Xeris Biopharma Holdings (XERS) in Q1 2025, closing a stake of 22,116 shares — an estimated $75K sold.

Savant Capital first reported a position in XERS in Q3 2024 and held it in 2 quarters. The position peaked at $75K in Q4 2024. 199 funds tracked by Wall St. Rank hold XERS as of Q1 2025.

Savant Capital reported no remaining Xeris Biopharma Holdings position as of Q1 2025 after selling out during the quarter.
Savant Capital sold 22,116 Xeris Biopharma Holdings shares in Q1 2025, an estimated $75K.
Savant Capital first reported a position in Xeris Biopharma Holdings in Q3 2024 and held it in 2 quarters.
Savant Capital's Xeris Biopharma Holdings position peaked at $75K in Q4 2024.
199 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2025.

Based on Savant Capital's 13F filing for Q1 2025, filed 8 May 2025.